Yuki Hanai

624 total citations
34 papers, 384 citations indexed

About

Yuki Hanai is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Yuki Hanai has authored 34 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 17 papers in Pharmacology and 12 papers in Epidemiology. Recurrent topics in Yuki Hanai's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), Antimicrobial Resistance in Staphylococcus (11 papers) and Bacterial Identification and Susceptibility Testing (8 papers). Yuki Hanai is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), Antimicrobial Resistance in Staphylococcus (11 papers) and Bacterial Identification and Susceptibility Testing (8 papers). Yuki Hanai collaborates with scholars based in Japan. Yuki Hanai's co-authors include Kazuaki Matsumoto, Toshimi Kimura, Yoshiko Takahashi, Yoshio Takesue, Yukihiro Hamada, Satoshi Fujii, Kazuhiro Matsuo, Shinobu Hirayama, Takashi Ueda and Toshihiko Mayumi and has published in prestigious journals such as Pharmaceutical Research, Journal of Antimicrobial Chemotherapy and British Journal of Clinical Pharmacology.

In The Last Decade

Yuki Hanai

30 papers receiving 382 citations

Peers

Countries citing papers authored by Yuki Hanai

Since Specialization

Citations

This map shows the geographic impact of Yuki Hanai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuki Hanai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuki Hanai more than expected).

Fields of papers citing papers by Yuki Hanai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuki Hanai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuki Hanai. The network helps show where Yuki Hanai may publish in the future.

Co-authorship network of co-authors of Yuki Hanai

This figure shows the co-authorship network connecting the top 25 collaborators of Yuki Hanai. A scholar is included among the top collaborators of Yuki Hanai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuki Hanai. Yuki Hanai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Consequences of reported β-lactam allergy on perioperative outcomes: a systematic review and meta-analysis of surgical site infection risk 2025 ·Infection Control and Hospital Epidemiology ·Yuki Hanai, Jun Hirai, Kazuhiro Matsuo, Keita Kouzu, Hiroji Shinkawa, Seiichi Shinji, (unknown), Yuko Kitagawa, Chizuru Yamashita, Yasuhiko Mohri, (unknown), Katsunori Suzuki, Junzo Shimizu, Motoi Uchino, Seiji Haji, Masahiro Yoshida, Toru Mizuguchi, Toshihiko Mayumi, Hiroki Ohge	0
2	Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan 2025 ·Antibiotics ·Jun Hirai, N. Môri, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo	0
3	Prediction of treatment success in patients with Enterococcus faecium bacteremia using vancomycin AUC24/MIC ratio: A multicenter retrospective study 2025 ·Diagnostic Microbiology and Infectious Disease ·Yuki Hanai, Kazuaki Matsumoto, (unknown), (unknown), (unknown), (unknown), Tetsuo Yamaguchi, Sohei Harada, (unknown), (unknown), (unknown), Ryuji Maruyama, (unknown), (unknown), (unknown), (unknown), Yuki Enoki, Kazuaki Taguchi, Kazuhiro Matsuo	1
4	Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study 2024 ·Cancer Medicine ·(unknown), (unknown), Yuki Hanai, (unknown), (unknown), (unknown), Takahiro Μatsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo	1
5	Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine 2024 ·Asian Journal of Psychiatry ·(unknown), (unknown), Yuki Hanai, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yūki Watanabe, (unknown), Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsuo	0
6	A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database 2024 ·Drugs - Real World Outcomes ·(unknown), (unknown), (unknown), Yuki Hanai, (unknown), Takashi Yoshio, Kazuhiro Matsuo	4
7	Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study 2023 ·Clinical and Translational Science ·Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto, Yuki Hanai, Takashi Ueda, (unknown), Akari Shigemi, Hirofumi Jono, Hideyuki Saito, Toshimi Kimura	11
8	Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study 2023 ·Pharmacology ·(unknown), (unknown), Yuki Hanai, (unknown), (unknown), (unknown), (unknown), Takahiro Μatsumoto, (unknown), Hidenari Nagai, Koji Higai, Kazuhiro Matsuo	4
9	Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study 2023 ·Clinical and Translational Science ·Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto, Yuki Hanai, Takashi Ueda, (unknown), Akari Shigemi, Hirofumi Jono, Hideyuki Saito, Toshimi Kimura	3
10	Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients 2023 ·Mycoses ·Yuki Hanai, Takashi Ueda, Yukihiro Hamada, Kazutaka Oda, Yoshiko Takahashi, Kazuhiko Nakajima, Yoshitsugu Miyazaki, (unknown), (unknown), Kazuhiro Matsuo, Kazuaki Matsumoto, Toshimi Kimura, Yoshio Takesue	6
11	Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring 2022 ·Clinical Therapeutics ·Yoshio Takesue, Yuki Hanai, Kazutaka Oda, Yukihiro Hamada, Takashi Ueda, Toshihiko Mayumi, Kazuaki Matsumoto, Satoshi Fujii, Yoshiko Takahashi, Yoshitsugu Miyazaki, Toshimi Kimura	37
12	Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring 2022 ·Pharmaceutics ·Kazuaki Matsumoto, Kazutaka Oda, Kensuke Shoji, Yuki Hanai, Yoshiko Takahashi, Satoshi Fujii, Yukihiro Hamada, Toshimi Kimura, Toshihiko Mayumi, Takashi Ueda, Kazuhiko Nakajima, Yoshio Takesue	78
13	Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir 2022 ·Diagnostic Microbiology and Infectious Disease ·Yuki Hanai, Sadako Yoshizawa, Kazuhiro Matsuo, (unknown), (unknown), Koji Nishimura, (unknown), Hayato Ohashi, Yoshikazu Ishii, Kazuhiro Tateda, Takashi Yoshio, (unknown)	4
14	Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis 2021 ·Journal of Fungi ·Yuki Hanai, Yukihiro Hamada, Toshimi Kimura, Kazuaki Matsumoto, Yoshiko Takahashi, Satoshi Fujii, (unknown), Yoshitsugu Miyazaki, Yoshio Takesue	24
15	Optimal trough concentration of teicoplanin for the treatment of methicillin‐resistant Staphylococcus aureus infection: A systematic review and meta‐analysis 2021 ·Journal of Clinical Pharmacy and Therapeutics ·Yuki Hanai, Yoshiko Takahashi, Takashi Niwa, Toshihiko Mayumi, Yukihiro Hamada, Toshimi Kimura, Kazuaki Matsumoto, Satoshi Fujii, Yoshio Takesue	17
16	Candidates for area under the concentration–time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients 2021 ·Journal of Global Antimicrobial Resistance ·(unknown), Toshimi Kimura, Yukihiro Hamada, Takashi Niwa, Yuki Hanai, Masayuki Chuma, Satoshi Fujii, Kazuaki Matsumoto, Akari Shigemi, Hideki Kawamura, Yoshiko Takahashi, Yoshio Takesue	18
17	Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis 2020 ·Journal of Infection and Chemotherapy ·Yuki Hanai, Yukihiro Hamada, Toshimi Kimura, Kazuaki Matsumoto, Yoshiko Takahashi, Satoshi Fujii, (unknown), Yoshio Takesue	20
18	A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa 2018 ·Journal of Infection and Chemotherapy ·Shinobu Hirayama, (unknown), Hinako Murakami, (unknown), Maki Sakamoto, Yuki Hanai, Kazuhiro Matsuo, (unknown), Yoshikazu Ishii, (unknown), Kazuhiro Tateda	4
19	A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia 2016 ·Journal of Infection and Chemotherapy ·Yuki Hanai, Kazuhiro Matsuo, Miki Ogawa, (unknown), (unknown), Shinobu Hirayama, (unknown), (unknown), Takashi Yoshio	91
20	Investigation of Voriconazole Pharmacokinetic Parameters to Schedule Safety Dosage 2013 ·Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ·Yuki Hanai, (unknown), (unknown), Koji Nishimura, (unknown), Kazuhiro Matsuo, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact